Últimas noticias sobre iBio (NASDAQ:IBIO) Bolsa

iBio

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

iBio Inc

Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) with a Buy and maintains $5 price target.

News

Price Target

Analyst Ratings

IBIO

Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target

WIIM

iBio shares are trading higher after the company announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60%.

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 172.2% to $25.97 during Tuesday's pre-market session. The company's market cap stands at $118.3 million. </li>
<li>InMed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) stock moved upwards by 88.53% to $4.62. The company's market cap stands at $2.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock increased by 53.21% to $0.84. The market value of their outstanding shares is at $10.5 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 47.43% to $1.05. The market value of their outstanding shares is at $11.5 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) stock rose 37.18% to $20.99. The market value of their outstanding shares is at $298.3 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 24.68% to $0.23. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 30.4% to $1.12 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares fell 19.35% to $0.4. The market value of their outstanding shares is at $8.0 million. </li>
<li>ViewBix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIX#NASDAQ">VBIX</a>) shares declined by 14.48% to $3.31. The company's market cap stands at $25.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 13.34% to $1.43. The market value of their outstanding shares is at $5.3 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock fell 11.39% to $1.09. The company's market cap stands at $19.0 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 11.05% to $0.21. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CASI

CBIO

DHAI

INDP

NKTR

PSTV

SNGX

TRIB

VBIX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<ul>
<li>Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist</li>
<li>Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases</li>
</ul>

Biotech

Health Care

General

iBio Announces Preclinical Data In Which An Engineered Amylin Receptor Agonist Antibody Reduced Acute Food Intake In A Mouse Model Of Obesity By 60%, Equivalent To The Reduction In Food Intake From A Clinically Advanced Dual Amylin And Calcitonin Receptor Agonist Peptide (67%).

Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) rose sharply in today's pre-market trading after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational <a href="https://www.benzinga.com/quote/NKTR">rezpegaldesleukin on June 24, 2025</a>.
Nektar Therapeutics shares jumped 30.3% to $12.44 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) surged 55.8% to $1.11 in pre-market trading after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.</li>
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) gained 27.7% to $0.2354 in pre-market trading after falling 5% on Monday.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) gained 20.1% to $12.44 in pre-market trading.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 18.5% to $23.74 in pre-market trading after jumping over 38% on Monday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 17.2% to $0.3089 in pre-market trading after gaining 7% on Monday. Adial Pharmaceuticals recently announced the pricing of a $3.6 million offering.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) climbed 16.2% to $2.23 in pre-market trading.</li>
<li>Rezolve AI PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 11.8% to $2.28 in pre-market trading. Rezolve AI shares gained around 6% on Monday after the company announced it will join the Russell 2000 and Russell 3000 indexes</li>
<li>WF Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) rose 9.2% to $7.10 in pre-market trading after dipping 6% on Monday.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) gained 5.8% to $8.36 in pre-market trading. Teladoc shares surged over 14% on Monday after Citron Research made comments about the company on social media.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares tumbled 62.3% to $3.77 in pre-market trading after gaining 8% on Monday.</li>
<li>Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) shares fell 52.4% to $4.73 in pre-market trading after jumping over 268% on Monday.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 39.2% to $15.06 in pre-market trading. DeFi Development rescheduled release of shareholder letter and business update call to July.</li>
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) declined 26.7% to $4.91 in pre-market trading after gaining 9% on Monday.</li>
<li>Indonesia Energy Corporation Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NASDAQ">INDO</a>) dipped 25.4% to $3.64 in pre-market trading after falling around 4% on Monday.</li>
<li>TMD Energy Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NYSE">TMDE</a>) fell 23.8% to $1.76 in pre-market trading after jumping 30% on Monday.</li>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) declined 22.1% to $1.16 in pre-market trading. Impact BioMedical shares jumped 345% on Monday after the company announced a limited merger and share exchange agreement with Dr Ashleys.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) fell 21.7% to $0.9160 in pre-market trading after jumping around 14% on Monday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 8.8% to $21.62 in pre-market trading after dipping 38% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) fell 8.2% to $4.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

ADIL

DFDV

INDO

LIMN

Highest Performances Holdings Inc. - American Depository Shares

MAAS

NINE

RBNE

RZLV

SRFM

TDOC

TMDE

UPXI

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

U.S. futures were trading higher on Tuesday after a positive day of trading on Monday. Futures of major benchmark indices were trading higher.
President Donald Trump announced a &#8220;<a href="https://www.benzinga.com/news/25/06/46066239/dow-futures-jump-over-200-points-as-trump-announces-ceasefire-but-iran-says-no-agreement-crude-plunges">ceasefire</a>&#8221; in a Truth Social post, saying that "THE 12 DAY WAR" will be considered "ended." 
Despite this, the Foreign Minister of Iran, Syed Abbas Araghchi, refuted claims of a ceasefire, saying that there was "no agreement" for cessation of military operations, in a post on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">As Iran has repeatedly made clear: Israel launched war on Iran, not the other way around. As of now, there is NO &quot;agreement&quot; on any ceasefire or cessation of military operations. However, provided that the Israeli regime stops its illegal aggression against the Iranian people no…
&mdash; Seyed Abbas Araghchi (@araghchi) <a href="https://twitter.com/araghchi/status/1937311435882922420?ref_src=twsrc%5Etfw">June 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The 10-year Treasury bond yielded 4.35% and the two-year bond was at 3.84%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 77.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.69%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.79%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.18%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Tuesday. The SPY was up 0.83% at $605.11, while the QQQ advanced 1.11% to $537.56, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Monday, U.S. stocks saw gains across most S&amp;P 500 sectors, with consumer discretionary, consumer staples, and real estate stocks leading the charge, though energy stocks diverged, ending the session in the red.
Economically, the S&amp;P Global US services PMI dropped to 53.1 in June from 53.7 the prior month, falling short of market expectations of 52.9. Meanwhile, the S&amp;P Global US manufacturing PMI held steady at 52 in June, matching the previous month's figure.
Shares of FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) rose approximately 3.5% on Monday after the company released its third-quarter results.
The Dow Jones index ended 375 points or 0.89% higher at 42,581.78, whereas the S&amp;P 500 index rose 0.96% to 6,025.17. Nasdaq Composite advanced 0.94% to 19,630.98, and the small-cap gauge, Russell 2000, gained 1.11% to end at 2,132.68.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.94%</td>
<td>19,630.98</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.96%</td>
<td>6,025.17</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.89%</td>
<td>42,581.78</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.11%</td>
<td>2,132.68</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Senior economist Jeremy Siegel expressed his opinions on the ongoing tensions as Trump announced a ceasefire.
&#8220;Geopolitics is a wildcard, but the U.S. is far less exposed than it was in the 1970s. Even a brief closure of the Strait of Hormuz would not derail domestic growth—shale capacity and strategic reserves mute the blow,&#8221; he said.
&#8220;I maintain that investors should stay overweight equities versus bonds,&#8221; he added, sayin that &#8220;don't just chase the AI enablers at high multiples to earnings; real margin expansion could very well accrue to users of AI—banks, industrial, consumer-staples, mid-cap firms that are learning where they can cut costs, increase output and improve margins.&#8221;
In its most recent note, BlackRock spotlighted the <a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-">defense sector as a top investment prospect</a>, fueled by escalating geopolitical fragmentation and a worldwide focus on national security.
As per BlackRock, the U.S. distinguishes itself through its extensive defense spending, which, according to SIPRI data, "spends more than double on defense than Europe."
Moreover, the U.S. hosts the world's most advanced defense and defense technology companies, acting as a vital provider of critical systems like air and missile defense for numerous countries.
Within the defense sector, BlackRock identifies substantial opportunities in defense tech. This expansive field includes not just artificial intelligence (AI) and software firms but also crucial IT services and hardware, such as semiconductors, that drive cutting-edge defense capabilities.
BlackRock observes that "growing geopolitical fragmentation and strategic competition in AI are reinforcing the global focus on national security and resilience – creating opportunities in defense." This highlights a targeted investment strategy in defense, where technological leadership and strong national security frameworks are increasingly critical.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s S&amp;P Case-Shiller home price index for 20 cities will be released by 9:00 a.m., and Cleveland Fed President Beth Hammack will speak at 9:15 a.m. ET.</li>
<li>June consumer confidence data will be out by 10:00 a.m., and the Fed Chairman Jerome Powell will testify to the House Financial Services Committee at 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>TD Synnex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) was up 0.58% in premarket on Tuesday as analysts expect it to report quarterly earnings of $2.72 per share on revenue of $14.32 billion, before the opening bell.</li>
<li>Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) rose 2.04% as analysts expect it to report quarterly earnings of 24 cents per share on revenue of $6.21 billion, before the opening bell.</li>
<li>Worthington Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) advanced 3.55% as analysts expect it to report quarterly earnings of 84 cents per share on revenue of $301.44 million, before the opening bell.</li>
<li>FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was 0.47% higher as analysts expect it to report quarterly earnings of $5.87 per share on revenue of $21.84 billion after the closing bell.</li>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) was down 0.43% as it revised full-year 2025 housing revenue to be in the range of $6.3 billion to $6.5 billion, down from prior guidance of $6.6 billion to $7 billion.</li>
<li>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) dropped 1.31% as it commenced an underwritten public offering of $1 billion of its Class A common stock by a selling stockholder. It plans to concurrently repurchase $100 million of its common stock from the selling stockholder.</li>
<li>BlackBerry Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) jumped 1.62% as analysts expect it to report quarterly earnings of $0 per share on revenue of $112.19 million after the closing bell.</li>
<li>Ibio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) surged 44.58% after it announced a conference call scheduled for June 24 to discuss its obesity and cardiometabolic disease pipeline.</li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) zoomed 31.66% ahead of its investor call, where it plans to present top-line data from the 16-week induction period of its Phase 2b REZOLVE-AD clinical trial.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.40% to hover around $66.18 per barrel.
Gold Spot US Dollar fell 1.29% to hover around $3,325.68 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.30% at the 98.1240 level.
Asian markets ended higher on Tuesday as Australia's ASX 200, Japan's Nikkei 225, China&#8217;s CSI 300, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex indices advanced. European markets were also higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

CHWY

US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock moved upwards by 53.8% to $3.86 during Monday's after-market session. The company's market cap stands at $111.3 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock increased by 42.3% to $1.02. The market value of their outstanding shares is at $12.5 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 22.11% to $11.65. The market value of their outstanding shares is at $105.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock moved upwards by 14.96% to $3.15. The company's market cap stands at $4.2 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock rose 9.82% to $0.28. The market value of their outstanding shares is at $15.8 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 9.22% to $9.0. The market value of their outstanding shares is at $5.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock fell 19.3% to $1.3 during Monday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock decreased by 6.88% to $0.28. The company's market cap stands at $1.1 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock declined by 6.87% to $1.9. The market value of their outstanding shares is at $75.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares declined by 5.87% to $0.43. The market value of their outstanding shares is at $18.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares decreased by 5.36% to $0.22. The company's market cap stands at $12.6 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock declined by 5.29% to $0.86. The company's market cap stands at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

CARM

CERO

CGTX

FEMY

HURA

NUWE

XBIO

12 Health Care Stocks Moving In Monday's After-Market Session

iBio shares ae trading higher after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.

Review of promising Myostatin and Activin E antibody data
iBio to announce 3rd target in Astral Bio Collaboration
Conference call Tuesday, June 24 at 8:30 a.m. ET
<a href="https://www.globenewswire.com/Tracker?data=AArIgDBHU7xoOYsPhyFqgHmp9hnOyBxFIwReOocYsVhUsyHdt0HELqAT5nkY2-NvTOFKZysrKo5vuluNqWWsolH1eAUYPlVzHJMQs2AwFS_S363D_8gFOxCtAYL6rPoBVeryWdyrYE6IbE7PstmEnmq1lgU9TGQ6kDcs6TY-mSO_X9V82QlcMVrjZNegNxBGpArYzANbikBKvZqlS_IIFEMfyk2aQX1RInx5boJhrN6W4vDaAZMlJ-Gka7y94HkApfWSLgru2lP-1h9LJRfDqsdkJLNTFzd9871KOUrlkJeZdFz6zB7kvrcSNgrUDXf19zP9kywg-EEvmd-QwPeDT7D98Sd7C_98qPc0Cgo_pyB1XUAEg7vVTjwG-CFszDbuyBa0wo6kcukWdu87wPOMoF42mqXaoAPnmU6A3U_3Nzg=">iBio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E. Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, <a href="https://www.globenewswire.com/Tracker?data=DUeYYeu_KTZc3S5Lr7e0MEImgLOjkEenZSVPu9vdxbKg9ysh7udoahEdmXfDiQSbapGzX0LkUy9wO_-6lmUguFGaniGhmtGBUuj8flh81RkZx6j7xjmoSuWusuwjBrmjU33jqQT2fSeNHKW-sBlj4OojSLfq4cX7dt-BVsQyv9SB9RrB9iBlByiJwGviyLWN49WQNBhSJlmLNhtKxYDwIg==">IBIO-600</a>, new preclinical data on <a href="https://www.globenewswire.com/Tracker?data=X8miJpcOvA9ijW6OUSgvClZSr5OVJo__yQdOQmPwqO0gN7ShWyZK2NCZiwwM11uR3eK5_wafYdyIvO1GQ6lnWPlbKY2VnTTgHyFd2Gz-aiyIgUNOh-MlVVePTma85YmrCEX7Fhio6WNS9Qh-sc5PgNUxsj89wqcVfUO9YqSO2atCm4eGDx7FHFWfdXJLMb0CXJbRlcjweP8_cr9znTRUyg==">Activin E</a> and, more safe and effective treatment options. The webcast of the live call may be accessed on the Investors section of the iBio website at <a href="https://www.globenewswire.com/Tracker?data=RlMXqtQRbFXTb3NRFmKX1uY-9KEOztuLOayq3Po1ZRsTjefAYQqS9vXyTuam6VR0CkCeSdvdReFwqKsg6DhoUE3-W8xVxbfhxFafgsXrMXBkxCGL6wX23Gj-9fzHIqj0tyzGOp86jg-pt0WW-WnCrw==">ir.ibioinc.com/news-events/ir-calendar</a>. A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation. &nbsp;

ibio Announces It Will Host  Conference Call On Tuesday, June 24, At 8:30 A.M. EST To Review Its Latest Advances In Obesity And Cardiometabolic Disease Treatments And Announce A Third Target In The Astralbio Collaboration In Addition To Myostatin And Activin E

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 8.8% to $0.3 during Tuesday's after-market session. The market value of their outstanding shares is at $18.8 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 8.14% to $0.69. The market value of their outstanding shares is at $111.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 8.0% to $0.88. The company's market cap stands at $14.5 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock moved upwards by 7.77% to $0.97. The company's market cap stands at $14.7 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 6.66% to $1.12. The market value of their outstanding shares is at $2.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 6.36% to $0.33. The market value of their outstanding shares is at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 26.2% to $2.14 during Tuesday's after-market session. The market value of their outstanding shares is at $77.5 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) stock decreased by 16.76% to $3.08. The company's market cap stands at $204.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock decreased by 16.26% to $0.24. The company's market cap stands at $20.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 14.35% to $5.97. The market value of their outstanding shares is at $17.2 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares declined by 8.28% to $0.75. The market value of their outstanding shares is at $17.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 6.89% to $4.8. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

BMEA

CRDF

EYEN

GOVX

HSDT

IRWD

SLRX

XAIR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<ul>
<li>iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody</li>
<li>New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition</li>
<li>Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%&#x2A;, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd</li>
</ul>

iBio Initiates Non-human Primate Study For Its Activin E Engineered Antibody Candidate, Now Named IBIO-610. This Preclinical Study Will Evaluate The Pharmacokinetics And Early Signs Of Efficacy Of IBIO-610 In Obese And Elderly NHPs, Including Its Impact On Fat And Body Composition

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 106.2% to $0.95 during Monday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock rose 22.22% to $2.2. The company's market cap stands at $10.8 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares rose 15.63% to $3.78. The company's market cap stands at $30.5 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares rose 14.89% to $10.26. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock moved upwards by 14.88% to $1.16. The company's market cap stands at $11.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares rose 11.31% to $6.79. The market value of their outstanding shares is at $139.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock declined by 89.9% to $1.7 during Monday's pre-market session. The company's market cap stands at $104.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 21.53% to $0.59. The market value of their outstanding shares is at $6.7 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 21.32% to $0.4. The market value of their outstanding shares is at $9.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 16.21% to $1.5. The market value of their outstanding shares is at $19.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock decreased by 14.39% to $1.25. The market value of their outstanding shares is at $17.9 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined by 14.09% to $0.43. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

APVO

BCRX

MODV

NCNA

PLRX

QNRX

RNAZ

12 Health Care Stocks Moving In Monday's Pre-Market Session

<ul>
<li>Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle</li>
<li>Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone &nbsp;</li>
</ul>
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its <a href="https://www.globenewswire.com/Tracker?data=jh7cCF2OKqZ5xu_O7XfSQMo5p4tDPzgs2pnT-iqyweEskYWjs3pWmGeg0UU9p-1sLO-OAMW4fUD5GJH3wlT1lS3ZmKFHypTyXv9k6JFLEBYJ1Fd41VG46I42nxZN6DKykZOR4IQiEdJO-XqZJqAh9eoPBGE_pzhRP0yG5YTDrGUrhEOqKQcSFu-yWO61sjwsdGYlfPPtX0sotkFG3tD5epWenlMuClx2K8jl3ZeJIbnNhgdEe_Di_I4e77VLcz-QgfIBhT1Lsj3IOKGO_hw0tA==">first-in-class Activin E antibody unveiled in January</a>. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs.
GLP-1 receptor agonists are effective at promoting weight loss. However, they can also reduce lean body mass, including muscle, which may limit some of the intended health benefits. In contrast, fat-specific weight loss is considered a higher-quality form of weight loss. It reduces fat—linked to lower risk of heart and metabolic diseases—while preserving muscle, which helps maintain strength, supports a healthy metabolism, and may prevent or reduce weight regain over time.

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss And Shows Synergy With GLP-1s In Preclinical Model; Strong Synergistic Effect On Fat Mass (77% Reduction) Was Observed When The Activin E Antibody Was Combined With A GLP-1 Receptor Agonist, Resulting In Total Weight Loss Of 35.3%, 7.5% Greater Than GLP-1 Alone

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 30.99 percent increase over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Misses

iBio Q3 EPS $(0.49) Misses $(0.34) Estimate

iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Institutional Investors Exercise iBio Warrants At Reduced Exercise Price Of $1.11/Shr Resulting In Gross Proceeds Of About $6.2M

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 50.4% to $0.02 during Tuesday's regular session. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) stock rose 39.13% to $4.97. The market value of their outstanding shares is at $30.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares increased by 33.48% to $5.74. The market value of their outstanding shares is at $3.0 million. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares moved upwards by 32.78% to $8.1. The market value of their outstanding shares is at $361.1 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 27.14% to $1.33. The market value of their outstanding shares is at $13.1 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock rose 26.12% to $35.92. The company's market cap stands at $8.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 71.0% to $0.02 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares decreased by 34.63% to $9.25. The company's market cap stands at $438.3 million. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock declined by 31.9% to $6.79. The market value of their outstanding shares is at $872.2 million. The company's, Q1 earnings came out today. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 25.2% to $4.84. The company's market cap stands at $2.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 23.37% to $4.56. The company's market cap stands at $69.4 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 15.99% to $0.3. The company's market cap stands at $9.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KALA

LFMD

LGMK

NDRA

PTPI

RLMD

TIVC

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 34.5% to $0.01 during Monday's regular session. </li>
<li>CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) shares moved upwards by 32.81% to $29.71. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) stock rose 32.18% to $13.8. The company's market cap stands at $654.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares moved upwards by 30.56% to $1.2. The company's market cap stands at $11.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 24.21% to $2.36. The company's market cap stands at $22.2 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 24.0% to $1.21. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 26.2% to $0.1 during Monday's regular session. The company's market cap stands at $3.9 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 22.6% to $0.89. The company's market cap stands at $3.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 20.8% to $3.96. The market value of their outstanding shares is at $102.9 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 18.94% to $0.26. The market value of their outstanding shares is at $13.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 18.74% to $0.15. The company's market cap stands at $6.7 million. </li>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock declined by 18.52% to $3.52. The company's market cap stands at $129.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

CGON

GELS

HCTI

SILO

SNTI

SPRB

TARA

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock moved upwards by 236.7% to $3.03 during Tuesday's regular session. The company's market cap stands at $28.5 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 138.27% to $2.43. The market value of their outstanding shares is at $33.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 121.42% to $7.75. The company's market cap stands at $4.7 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock moved upwards by 58.85% to $14.44. The company's market cap stands at $23.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 30.59% to $0.84. The company's market cap stands at $4.9 million. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock moved upwards by 28.97% to $1.38. The market value of their outstanding shares is at $550.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares decreased by 28.0% to $0.1 during Tuesday's regular session. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock fell 17.91% to $0.7. The company's market cap stands at $6.8 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares fell 16.39% to $3.93. The company's market cap stands at $20.5 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares fell 13.49% to $4.17. The company's market cap stands at $186.7 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock declined by 11.56% to $1.06. The company's market cap stands at $16.4 million. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares decreased by 10.64% to $2.94. The company's market cap stands at $17.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

PRTG

SCLX

SXTC

VINC

YMAB

<a href="https://www.globenewswire.com/Tracker?data=yfZ2eSHDjFlismVQ22s7M9ahGIsxc_c3JjmLemcisJobsa7peXhySiz3DFrXLtooq_g_f-kPedb-852zUon7n4qfGS2joB0T27fsCeHHKYYtw-aQJo35C-X1FD-BX-FCvZKlVgEPP51WycSwzCraxE1fTU-LuVNL9f5gb1jMK_KlfH7jsUwMxcGVsDdKfbInO7SPuLXztF4TCyZm3-Hv7-SU6ahOnQyaTE3rbNNQK5z7ZGUaeN9zQncx-ehsALJgmYNDdESneNf5OfsvcU8U-V3wN1JkJaKsPN9NYHEEpn0P3cC8zJB6CXCLVVSVPrXhKTAQWCCT41fQ4Y75_sB5364FIFW_kWoJF0Nxt6gjl-aTyM8QDlzBZ4lIyPwMj960SXfgwL2CMfNxSm9lWOuz5Fm8GCIYi29ve90WTSwBYLs=">Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting <a href="https://www.globenewswire.com/Tracker?data=2Ap9Z7U3HayJzgEw3tx13uO0r3yrphLjM4Fi4nyTVJEqF6LUdjUxq6W1UgaoCpDR75nPmjcAH8gb-akQ4d42b5HGP6n3FFxu1Qkm-WC59rkA-ng-syij9rLfgJySEkoIxhNkLegX__IsPydEZJE4NlyR2eXOPVvZOiUgxwB7AGnX2GiO65WX8MFHRXhdOEHFA3Dzvy-sBaE9Sn_-1m20PCjJDQaFHfLkGEPIZMSXjt3YHpCw2DMICI9FQYGVK_G907DW4sbDJM7sE6WUQhC2jzuivj8nFSylTCkdzLzgt45ZRPJL8w-PMf4g7QEEJ7CE">Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine</a>. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to rapidly advance testing of the antibody in more complex models following preclinical studies that demonstrated strong antibody binding, inhibition of Activin E signaling and fat-specific weight loss in an obese rodent animal model.
The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in regulating energy balance and fat distribution. Inhibiting Activin E-mediated signaling could offer a novel therapeutic strategy to reduce internal abdominal fat while preserving muscle mass—potentially reversing obesity, preventing diabetes, and improving overall cardiometabolic health. As one of several cellular components involved in cardiometabolic regulation, Activin E, along with amylin, GLP-1 and others, are part of a broader network of signaling pathways that have the potential to be targeted simultaneously to yield synergistic benefits for patients.
Using its proprietary Machine Learning Antibody Engine and advanced epitope engineering technology, iBio designed engineered epitopes representing five key regions of the Activin E protein. This approach led to the successful development of a molecule that fully blocks Activin E-mediated signaling and inhibits its function across multiple in vitro models. In vivo proof-of-concept was established in a rodent model of obesity, where the antibody induced fat-selective weight loss as a monotherapy and showed synergistic weight loss when added to a GLP-1 receptor agonist in <a href="https://www.globenewswire.com/Tracker?data=IC6CnWZUDTXt2k2kQcI4UJS1sr27bCIdXB-9lKCH8hUbHT9eSX6RDqG0dYhVJoP0JKTOGoC1X4gdoMxNyQ8ynAHTRfFgqQKESrJ9tavPegKHu6w_bc9eAAY8NIS3PlJpiOr4wMu1FUImPpFwVI8vsHJnGXMEZTaiaFlygE1a550MScR6WC_Is1iLv-scMHL1eGjJQKeszBIQMEDM0twrdJ-WOs-WEx9vGSAr96a0bJg=">recently published data</a> by iBio. iBio plans to present additional preclinical data of its antibody targeting Activin E at the International BMP Conference, taking place in Philadelphia, PA, from May 2–6.
"Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic target and our confidence in building upon the strong preclinical data we recently published," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "This antibody represents a strategic expansion of our pipeline in cardiometabolic diseases and obesity and a significant step toward clinical development of a medication that can potentially offer meaningful benefits to patients."

iBio, Announces A Licensing Agreement With Astralbio For A Preclinical First-In-Class Antibody Targeting Activin E

Press Releases

iBio Reports Fiscal Second Quarter 2025 Financial Results

Markets

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Financing

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Comments

iBio

Noticias

Últimas noticias sobre iBio (NASDAQ:IBIO) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL